



PATIENT ORGANIZATIONS ARE HELPING FINANCE THE CLINIC

Two FSHD candidates entered clinical development this year with capital contributed by advocacy organizations.

THE EVIDENCE, 2026

TWO DEALS IN THREE MONTHS

JULY

US\$3.7 million behind Cyclo-Z, an oral muscle-preserving candidate from NovMetaPharma.

SEPTEMBER

Up to US\$5 million behind forazapadin from Satellos Bioscience, now cleared by the FDA to enter Phase 2.

ON WHAT TERMS

NOT A GRANT. NOT A DONATION.

This is capital placed into a clinical development program, structured with milestones and a revenue-sharing interest in future FSHD proceeds.

The companies keep ownership and global rights. The foundation takes a position, on behalf of patients.



AND STILL

NO ORGANIZATION DID THIS ALONE

Both deals rest on support from patient organizations in other countries: Canada, the United States and Australia.

4 organizations.

3 continents.

2 candidates on a route into the clinic.

WHY IT MATTERS

THIS MODEL BELONGS TO THE FIELD

Few organizations could do this alone, and none had to. What one country proves, the others can adopt.

Project Mercury's toolkit and readiness work transfer to the World FSHD Alliance, so no one rebuilds what has already been built.

**Read the full story at
projectmercuryfshd.org/blog**

